TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 1, 2014, Pages 51-58

  Yu, Hai Ming ^a   Yang, Jun Lan ^a   Jiao, Shun Chang ^a   Wang, Jian Dong ^a   Li, Ying ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

adjuvant chemotherapy; adjuvant endocrine therapy; breast cancer; CD8; disease free survival; distant disease free survival; overall survival; TGF 1

Indexed keywords

PROTEIN PRECURSOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICS;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84894075532     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1231-2     Document Type: Article

References (24)

1. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA, 2005, 102(2):419-424
2. Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4.T cells to T-regulatory cells. Cancer Res, 2011,71(10):3505-3515
3. Xu L, Xu W, Wen Z, et al. In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity. PLoS One, 2011,6(5):e20282
4. Yu J, Wei M, Becknell B, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity, 2006,24(5):575-590
5. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 2008, 13(1):23-35
6. Laoui D, Movahedi K, Van Overmeire E, et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol, 2011,55(7-9): 861-867
7. Hung SP, Yang MH, Tseng KF, et al. Hypoxia-induced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant, 2013,22(10):1869-1882
8. Filaci G, Suciu-Foca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity? Autoimmun Rev, 2002,1(5):279-283
9. Murri AM, Hilmy M, Bell J, et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer, 2008, 99(7):1013-1019
10. Lee AH, Happerfield LC, Bobrow LG, et al. Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol, 1997,181(2):200-206
11. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res, 2011,13(5):R97
12. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med, 2008, 14(5):518-527
13. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol, 2011,29(15): 1949-1955
14. Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res, 2012,14(2):R48
15. DeNardo DG, Brennan DJ, Rexhepaj E. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov, 2011,(1):54-67
16. West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res, 2011,13(6):R126
17. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res, 2008,14(8):2413-2420
18. Rody A, Holtrich U, Pusztai L, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res, 2009,11(2):R15
19. Emens LA. Chemoimmunotherapy. Cancer J, 2010,16(4): 295-303
20. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 2008,133(1):66-77
21. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest, 1993, 92(6):2569-2576
22. Bluff JE, Menakuru SR, Cross SS, et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer, 2009,18;101(4):666-672
23. Imai K, Minamiya Y, Koyota S, et al. Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res, 2012,31:3
24. Lee GT, Hong JH, Kwak C, et al. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res, 2007,67(14):6717-6724